Literature DB >> 26974270

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

F Baron1, Y Beguin1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26974270     DOI： 10.1038/bmt.2016.38

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  23 in total

1.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Christoph Schmid; Michael Schleuning; Georg Ledderose; Johanna Tischer; Hans-Jochem Kolb
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

Authors:  Jurjen Versluis; Carin L E Hazenberg; Jakob R Passweg; Wim L J van Putten; Johan Maertens; Bart J Biemond; Matthias Theobald; Carlos Graux; Jurgen Kuball; Harry C Schouten; Thomas Pabst; Bob Löwenberg; Gert Ossenkoppele; Edo Vellenga; Jan J Cornelissen
Journal:  Lancet Haematol       Date:  2015-09-18       Impact factor: 18.959

Review 3.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.

Authors:  Eva Rettinger; Andre M Willasch; Hermann Kreyenberg; Arndt Borkhardt; Wolfgang Holter; Bernhard Kremens; Brigitte Strahm; Wilhelm Woessmann; Christine Mauz-Koerholz; Bernd Gruhn; Stefan Burdach; Michael H Albert; Paul-Gerhardt Schlegel; Thomas Klingebiel; Peter Bader
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

5.  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

Authors:  Z Jedlickova; C Schmid; C Koenecke; B Hertenstein; H Baurmann; R Schwerdtfeger; J Tischer; H-J Kolb; M Schleuning
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

6.  High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

Authors:  Maria Liga; Evangelia Triantafyllou; Maria Tiniakou; Polyxeni Lambropoulou; Marina Karakantza; Nicholas C Zoumbos; Alexandros Spyridonidis
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-04       Impact factor: 5.742

7.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Authors:  Oliver C Goodyear; Mike Dennis; Nadira Y Jilani; Justin Loke; Shamyla Siddique; Gordon Ryan; Jane Nunnick; Rahela Khanum; Manoj Raghavan; Mark Cook; John A Snowden; Mike Griffiths; Nigel Russell; John Yin; Charles Crawley; Gordon Cook; Paresh Vyas; Paul Moss; Ram Malladi; Charles F Craddock
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

8.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

9.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

Review 10.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Paresh Vyas; Frederick R Appelbaum; Charles Craddock
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-13       Impact factor: 5.742
View more
  4 in total

Review 1.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 2.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Authors:  Melanie L Grant; Catherine M Bollard
Journal:  Blood Rev       Date:  2017-11-27       Impact factor: 8.250

Review 4.  Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.

Authors:  Saeed Mohammadi; Amir Hossein Norooznezhad; Ashraf Malek Mohammadi; Hajar Nasiri; Mohsen Nikbakht; Najmaldin Saki; Mohammad Vaezi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Exp Hematol Oncol       Date:  2017-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.